Asllanaj, E.* ; Zhang, X.* ; Ochoa Rosales, C.* ; Nano, J. ; Bramer, W.M.* ; Portilla-Fernandez, E.* ; Braun, K.V.E.* ; Gonzalez-Jaramillo, V.* ; Ahrens, W.* ; Ikram, A.* ; Ghanbari, M.* ; Voortman, T.* ; Franco, O.H.* ; Muka, T.* ; Glisic, M.*
Sexually dimorphic DNA-methylation in cardiometabolic health: A systematic review.
Maturitas 135, 6-26 (2020)
Sex is a major determinant of cardiometabolic risk. DNA methylation (DNAm), an important epigenetic mechanism that differs between sexes, has been associated with cardiometabolic diseases. Therefore, we aimed to systematically review studies in adults investigating sex-specific associations of DNAm with intermediate cardiometabolic traits and incident cardiovascular disease including stroke, myocardial infarction (MI) and coronary heart disease (CHD). Five bibliographic databases were searched from inception to 15 July 2019. We selected 35 articles (based on 30 unique studies) from 17,023 references identified, with a total of 14,020 participants of European, North American or Asian ancestry. Four studies reported sex differences between global DNAm and blood lipid levels and stroke risk. In 25 studies that took a genome wide or candidate gene approach, DNAm at 31 gene sites was associated with sex differences in cardiometabolic diseases. The identified genes were PLA2G7, BCL11A, KDM6A, LIPC, ABCG1, PLTP, CETP, ADD1, CNN1B, HOOK2, GFBP-7,PTPN1, GCK, PTX3, ABCG1, GALNT2, CDKN2B, APOE, CTH, GNASAS, INS, PON1, TCN2, CBS, AMT, KDMA6A, FTO, MAP3K13, CCDC8, MMP-2 and ER-a. Prioritized pathway connectivity analysis associated these genes with biological pathways such as vitamin B12 metabolism, statin pathway, plasma lipoprotein, plasma lipoprotein assembly, remodeling and clearance and cholesterol metabolism. Our findings suggest that DNAm might be a promising molecular strategy for understanding sex differences in the pathophysiology of cardiometabolic diseases and that future studies should investigate the effects of sex on epigenetic mechanisms in cardiometabolic risk. In addition, we emphasize the gap between the translational potential and the clinical utilization of cardiometabolic epigenetics.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Dna Methylation ; Type 2 Diabetes ; Coronary Disease ; Myocardial Infarction ; Stroke; Coronary-heart-disease; Genome-wide Association; Essential-hypertension; Epigenetic Regulation; Apolipoprotein-e; Lipid-levels; Cardiovascular-disease; Metabolic Syndrome; Gene-expression; Risk-factors
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2020
Prepublished im Jahr
HGF-Berichtsjahr
2020
ISSN (print) / ISBN
0378-5122
e-ISSN
0378-5122
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 135,
Heft: ,
Seiten: 6-26
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
Elsevier
Verlagsort
Elsevier House, Brookvale Plaza, East Park Shannon, Co, Clare, 00000, Ireland
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Epidemiology (EPI)
POF Topic(s)
30202 - Environmental Health
90000 - German Center for Diabetes Research
Forschungsfeld(er)
Genetics and Epidemiology
PSP-Element(e)
G-504000-002
G-504000-010
G-501900-401
Förderungen
Copyright
Erfassungsdatum
2020-03-11